ErSO
Experimental cancer drug
| ErSO | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
ErSO is an experimental cancer drug that has shown promise in preclinical studies for the treatment of estrogen receptor-positive breast cancer. It is designed to target and exploit the estrogen receptor (ER) pathway, which is a common driver in many breast cancers.
Mechanism of Action[edit | edit source]
ErSO works by binding to the estrogen receptor in a unique way that differs from traditional endocrine therapy drugs. While most ER-targeting drugs aim to block the receptor, ErSO activates a stress response pathway that leads to the selective killing of cancer cells. This mechanism involves the activation of the unfolded protein response (UPR), which is a cellular stress response related to the endoplasmic reticulum.
Preclinical Studies[edit | edit source]
In preclinical models, ErSO has demonstrated significant efficacy in reducing tumor size in mouse models of ER-positive breast cancer. The drug was able to shrink tumors rapidly and effectively, with minimal impact on normal tissues. These studies suggest that ErSO could potentially overcome resistance to existing ER-targeted therapies.
Potential Benefits[edit | edit source]
The unique mechanism of ErSO offers several potential benefits over existing therapies:
- Selective Targeting: By exploiting the stress response pathway, ErSO selectively targets cancer cells while sparing normal cells.
- Overcoming Resistance: ErSO may be effective in cases where tumors have developed resistance to other ER-targeted therapies.
- Rapid Action: Preclinical studies have shown that ErSO can rapidly reduce tumor size, which could translate to faster clinical responses.
Development and Future Directions[edit | edit source]
ErSO is currently in the preclinical stage of development. Further studies are needed to evaluate its safety and efficacy in humans. If successful, ErSO could represent a new class of ER-targeted therapies with the potential to improve outcomes for patients with ER-positive breast cancer.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
